image
Healthcare - Medical - Devices - NASDAQ - US
$ 7.61
-1.81 %
$ 477 M
Market Cap
-8.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMCI stock under the worst case scenario is HIDDEN Compared to the current market price of 7.61 USD, Treace Medical Concepts, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMCI stock under the base case scenario is HIDDEN Compared to the current market price of 7.61 USD, Treace Medical Concepts, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMCI stock under the best case scenario is HIDDEN Compared to the current market price of 7.61 USD, Treace Medical Concepts, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TMCI

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
209 M REVENUE
11.89%
-55.7 M OPERATING INCOME
-8.28%
-55.7 M NET INCOME
-12.55%
-37.2 M OPERATING CASH FLOW
-7.50%
35.4 M INVESTING CASH FLOW
143.51%
160 K FINANCING CASH FLOW
-99.85%
68.7 M REVENUE
52.39%
-204 K OPERATING INCOME
98.65%
-501 K NET INCOME
96.74%
-4.21 M OPERATING CASH FLOW
64.47%
3.42 M INVESTING CASH FLOW
-40.64%
26 K FINANCING CASH FLOW
225.00%
Balance Sheet Treace Medical Concepts, Inc.
image
Current Assets 161 M
Cash & Short-Term Investments 75.7 M
Receivables 40.8 M
Other Current Assets 44.9 M
Non-Current Assets 55.7 M
Long-Term Investments 0
PP&E 34.4 M
Other Non-Current Assets 21.3 M
34.86 %18.80 %20.69 %15.84 %9.81 %Total Assets$217.1m
Current Liabilities 34.9 M
Accounts Payable 10.5 M
Short-Term Debt 413 K
Other Current Liabilities 24 M
Non-Current Liabilities 69.3 M
Long-Term Debt 69.2 M
Other Non-Current Liabilities 37 K
10.10 %23.02 %66.45 %Total Liabilities$104.2m
EFFICIENCY
Earnings Waterfall Treace Medical Concepts, Inc.
image
Revenue 209 M
Cost Of Revenue 41.1 M
Gross Profit 168 M
Operating Expenses 224 M
Operating Income -55.7 M
Other Expenses 55 K
Net Income -55.7 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)209m(41m)168m(224m)(56m)(55k)(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.37% GROSS MARGIN
80.37%
-26.60% OPERATING MARGIN
-26.60%
-26.63% NET MARGIN
-26.63%
-49.38% ROE
-49.38%
-25.68% ROA
-25.68%
-30.50% ROIC
-30.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Treace Medical Concepts, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)202020202021202120222022202320232024202420252025
Net Income -55.7 M
Depreciation & Amortization 8.42 M
Capital Expenditures -11.6 M
Stock-Based Compensation 0
Change in Working Capital 0
Others 1.73 M
Free Cash Flow -48.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Treace Medical Concepts, Inc.
image
Wall Street analysts predict an average 1-year price target for TMCI of $11.6 , with forecasts ranging from a low of $6.5 to a high of $16 .
TMCI Lowest Price Target Wall Street Target
6.5 USD -14.59%
TMCI Average Price Target Wall Street Target
11.6 USD 52.76%
TMCI Highest Price Target Wall Street Target
16 USD 110.25%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Treace Medical Concepts, Inc.
image
Sold
0-3 MONTHS
398 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
524 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.28 M USD 2
6-9 MONTHS
6.03 M USD 6
9-12 MONTHS
7. News
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona. globenewswire.com - 3 weeks ago
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference Expands market-leading position with new best-in-class bunion technologies Expands market-leading position with new best-in-class bunion technologies globenewswire.com - 3 weeks ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
Treace Medical Concepts, Inc. (TMCI) Q4 2024 Earnings Call Transcript Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Securities Danielle Antalffy - UBS Ben Haynor - Lake Street Capital Markets Operator Welcome to the Treace Medical Concepts Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. seekingalpha.com - 1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.10 per share a year ago. zacks.com - 1 month ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
8. Profile Summary

Treace Medical Concepts, Inc. TMCI

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 477 M
Dividend Yield 0.00%
Description Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Contact 203 Fort Wade Road, Ponte Vedra, FL, 32081 https://www.treace.com
IPO Date April 23, 2021
Employees 477
Officers Mr. John T. Treace Chief Executive Officer, Founder & Director Mr. Taylor Erickson Chief Information & Cybersecurity Officer Mr. Scot M. Elder J.D. Chief Legal & Compliance Officer and Corporate Secretary Mr. Daniel E. Owens Chief Human Resources Officer Mr. Terry W. Lubben Chief Operations & Supply Chain Officer Ms. Rachel Osbeck Chief Strategic Initiatives Officer Mr. Mark L. Hair CPA Chief Financial Officer Mr. Aaron J. Berutti Senior Vice President of Sales Ms. Shana Zink Senior Vice President of Clinical Affairs & Reimbursement Dr. Sean F. Scanlan Ph.D. Chief Innovation Officer